1. Show article details.

    Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

    GlobeNewswire – 8:30 AM ET 05/19/2022

    A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication Science Translational Medicine has published the results of a Duke University-led preclinical hamster transmission study that found that Vaxart’s S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2.

  2. Show article details.

    Gainey McKenna & Egleston Investigates Potential Claims On Behalf of Investors of Vaxart, Inc. (VXRT)

    GlobeNewswire – 5:35 PM ET 05/13/2022

    Gainey McKenna & Egleston announces that it is investigating whether the directors and/or officers of Vaxart, Inc. (VXRT) breached their fiduciary duties of loyalty, good faith and candor and whether the Company suffered substantial harm as a result.

  3. Show article details.

    BRIEF-Vaxart Retained Fuad Ahmad As Co's Interim CFO, Search Ongoing For CFO

    Reuters – 5:42 PM ET 05/11/2022

    Vaxart Inc (VXRT): * Vaxart Inc (VXRT)- ON MAY 10 CO RETAINED FUAD AHMAD AS CO'S INTERIM CFO WHILE VAXART CONDUCTS ITS ONGOING SEARCH FOR A CHIEF FINANCIAL OFFICER Source text for Eikon: [https://bit.ly/3Pccrqn] Further company coverage:

  4. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 12:28 PM ET 05/11/2022

      On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.

  5. Show article details.

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    Benzinga – 8:22 AM ET 05/10/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  6. Show article details.

    BRIEF-Vaxart Reports First Quarter 2022 Financial Results

    Reuters – 5:47 PM ET 05/09/2022

    Vaxart Inc (VXRT): * VAXART PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS. * Q1 LOSS PER SHARE $0.20 Source text for Eikon: Further company coverage:

  7. Show article details.

    Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

    GlobeNewswire – 5:46 PM ET 05/09/2022

    Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1st Quarter with $157.0 million in cash, cash equivalents and marketable securities Vaxart (VXRT), Inc. issued its business update today for the first quarter of 2022, reporting continued progress on its oral vaccine candidates.

  8. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 3:31 PM ET 04/28/2022

      During Thursday, 849 stocks hit new 52-week lows. During the morning session of trading on Thursday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  9. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 2:41 PM ET 04/27/2022

      Wednesday's session saw 784 companies set new 52-week lows. The following stocks set new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.

  10. Show article details.

    Stocks That Hit 52-Week Lows On Tuesday

    Benzinga – 1:44 PM ET 04/26/2022

      During Tuesday, 581 stocks hit new 52-week lows. Meta Platforms was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was AnPac Bio-Medical Science. During Tuesday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  11. Show article details.

    Stocks That Hit 52-Week Lows On Monday

    Benzinga – 12:01 PM ET 04/25/2022

      On Monday, 721 companies achieved new lows for the year. During Monday, the following stocks set new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  12. Show article details.

    Stocks That Hit 52-Week Lows On Friday

    Benzinga – 12:26 PM ET 04/22/2022

      On Friday, 431 companies hit new 52-week lows. Here are all the stocks that set new 52-week lows on Friday: Be sure to stay with Benzinga for further updates and market-moving news.

  13. Show article details.

    Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

    GlobeNewswire – 8:30 AM ET 04/14/2022

    Vaxart, Inc. (VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.  The title of Dr. Tucker’s presentation is “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination.

  14. Show article details.

    Consumers Search for Suitable Alternatives to Supplement their Health

    PR Newswire – 9:00 AM ET 04/05/2022

    FinancialBuzz.com News Commentary NEW YORK, April 5, 2022 Recent data regarding the pandemic has revealed that hospitalizations and death rates are rising once again. As a result of the pandemic's unceasing nature, COVID-19 testing kits are in short supply.

  15. Show article details.

    Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

    GlobeNewswire – 4:05 PM ET 02/24/2022

    Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year Ended 2021 with $182.7 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 -- Vaxart (VXRT), Inc. issued its business updat...

  16. Show article details.

    BRIEF-Vaxart's S-Only Covid-19 Vaccine Candidate Produces Immune Responses In Non-Human Primates

    Reuters – 8:54 AM ET 02/24/2022

    Vaxart Inc (VXRT): * Vaxart Inc (VXRT) - VAXART'S S-ONLY COVID-19 VACCINE CANDIDATE PRODUCES STRONG-CROSS REACTIVE MUCOSAL AND SYSTEMIC IMMUNE RESPONSES IN NON-HUMAN PRIMATES. * Vaxart Inc (VXRT) - VAXART'S S-ONLY CANDIDATE INDUCED A 1000-FOLD INCREASE IN NASAL IGA RESPONSES TO VARIANTS, * Vaxart Inc (VXRT) - DATA IS EXPECTED IN FIRST HALF OF 2022.

  17. Show article details.

    Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

    GlobeNewswire – 8:30 AM ET 02/24/2022

    Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on re...

  18. Show article details.

    Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

    GlobeNewswire – 8:00 AM ET 02/14/2022

    Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team Vaxart (VXRT), Inc. today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective today. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences.

  19. Show article details.

    Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference

    GlobeNewswire – 8:00 AM ET 01/04/2022

    Vaxart, Inc. (VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a virtual fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

  20. Show article details.

    Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron

    GlobeNewswire – 8:00 AM ET 12/16/2021

    Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study Oral tablet’s immunogenicity profile suggests it may provide cross-protection against SARS-CoV-2 variants, including Omicron SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 -- Vaxart (VXRT), Inc. said today it plans to test the cross-reactivity of its oral tablet COVID-19 vaccine ...

Page:

Today's and Upcoming Events

  • Aug
    03

    VXRT to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    09

    VXRT announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.